In-Depth Market Analysis On Thrombocytopenia - Pipeline Review, H2 2016
Thrombocytopenia - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.
Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding.
To access full report with TOC, please visit Thrombocytopenia - Pipeline Review, H2 2016
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia.
Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)
- The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc. AkaRx Inc Amarillo Biosciences, Inc. Amgen Inc. arGEN-X BV BioLineRx, Ltd. Biotest AG Boehringer Ingelheim GmbH Bolder Biotechnology, Inc. Bristol-Myers Squibb Company Cellerant Therapeutics, Inc. Genosco Hansa Medical AB Immunomedics, Inc. Intas Pharmaceuticals Ltd. Jiangsu Hengrui Medicine Co., Ltd. Merck & Co., Inc. Momenta Pharmaceuticals, Inc. Myelo Therapeutics GmbH Neumedicines Inc. Novartis AG Pfizer Inc. PhytoHealth Corporation Prophylix Pharma AS Protalex, Inc. Rigel Pharmaceuticals, Inc. Shionogi & Co., Ltd. Shire Plc STATegics, Inc. UCB SA ViroMed Co Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 01:24
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home